Therapeutic strategies to overcome ALK resistance in cancer /

"Therapeutic Strategies to Overcome ALK Resistance in Cancer, Volume 13, presents current strategies to improve and prolong clinical benefit in ALK driven cancers. Most patients with ALK-driven cancer are sensitive to tyrosine kinase inhibitor (TKI) therapy, but resistance invariably develops....

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Friboulet, Luc (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London, United Kingdom : Academic Press, an imprint of Elsevier, [2021]
Colección:Cancer sensitizing agents for chemotherapy ; v. 13.
Temas:
Lungs > Cancer > Treatment.
Anaplastic Lymphoma Kinase > antagonists & inhibitors
Lung Neoplasms > drug therapy
Antineoplastic Agents > pharmacology
Protein Kinase Inhibitors > therapeutic use
Poumons > Cancer > Traitement.
Lungs > Cancer > Treatment
Internet Resources.
Index not Present.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Structure and function of ALK
  • ALK rearranged lung cancer: TKI treatment and outcome
  • Systemic treatments other than TKI: reflections on chemotherapy, immunotherapy and antiangiogenic agents in ALK-driven NSCLC
  • Management of ALK positive patients with tumors other than lung cancer (ALCL, neuroblastoma, inflammatory myofibroblastic tumor)
  • Resistance mechanisms to ALK TKIs in lung cancer: from single to compound mutations, from tissue to liquid biopsy
  • Resistance mechanisms to ALK TKI in tumors other than lung cancer
  • Therapeutic strategies to overcome ALK resistance in lung cancer
  • Novel therapeutic strategies to enhance crizotinib anti-tumor efficacy in ALCL: use of ACD
  • Drug combinations to enhance ALK TKI anti-tumor efficacy in neuroblastoma
  • State of the art and future perspectives.

Ejemplares similares